Astrazeneca (AZN) Notes Payables (2009 - 2026)
Astrazeneca (AZN) posted quarterly Notes Payables of -$597.0 million for Q1 2026, down 34.16% year-over-year from -$906.7 million in Q1 2025, and up 7.3% quarter-over-quarter from -$644.0 million in Q4 2025.
Astrazeneca (AZN) Notes Payables (2009 - 2026) Analysis & Trends
Astrazeneca's Notes Payables history runs 18 years deep, the most recent figure standing at -$597.0 million for Q1 2026.
- In Q1 2026, Notes Payables fell 34.16% year-over-year to -$597.0 million; the TTM figure through Mar 2026 stood at -$597.0 million (down 34.16% YoY), while the FY2025 annual figure was -$644.0 million, down 95.15% from the prior year.
- Notes Payables for Q1 2026 stood at -$597.0 million, up from -$644.0 million in the prior quarter.
- The five-year high for Notes Payables was $337.0 million in Q2 2022, with the low at -$805.0 million in Q1 2022.
- The 5-year median for Notes Payables is -$515.0 million (2023), against an average of -$388.8 million.
- The sharpest annual moves came in 2024 and 2025: Notes Payables jumped 35.92% in 2024, then tumbled 95.15% in 2025.
- Astrazeneca's Notes Payables stood at -$350.0 million in 2022, then tumbled by 47.14% to -$515.0 million in 2023, then surged by 35.92% to -$330.0 million in 2024, then slumped by 95.15% to -$644.0 million in 2025, then grew by 7.3% to -$597.0 million in 2026.
- Business Quant data shows AZN's Notes Payables at -$597.0 million in Q1 2026, -$644.0 million in Q4 2025, and -$622.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.88 Bn | 625.12 Bn | 17.26 Bn |
| 2 | AbbVie | 463.46 Bn | 456.89 Bn | 12.70 Bn |
| 3 | Merck | 367.92 Bn | 360.78 Bn | 12.21 Bn |
| 4 | Novartis Ag | 297.71 Bn | 290.02 Bn | 11.24 Bn |
| 5 | Astrazeneca | 255.55 Bn | 250.65 Bn | 12.86 Bn |
| 6 | Amgen | 234.52 Bn | 220.53 Bn | 7.24 Bn |
| 7 | Gilead Sciences | 178.22 Bn | 175.04 Bn | 6.22 Bn |
| 8 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn |
| 9 | Gsk | 105.32 Bn | 101.15 Bn | 8.24 Bn |
| 10 | Sanofi | 54.20 Bn | 46.82 Bn | 10.79 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -597.00 Mn |
| Dec 31, 2025 | -644.00 Mn |
| Sep 30, 2025 | -622.00 Mn |
| Jun 30, 2025 | 26.00 Mn |
| Mar 31, 2025 | -445.00 Mn |
| Dec 31, 2024 | -330.00 Mn |
| Sep 30, 2024 | -769.00 Mn |
| Jun 30, 2024 | 239.00 Mn |
| Mar 31, 2024 | -477.00 Mn |
| Dec 31, 2023 | -515.00 Mn |
| Sep 30, 2023 | -515.00 Mn |
| Jun 30, 2023 | 193.00 Mn |
| Mar 31, 2023 | -593.00 Mn |
| Dec 31, 2022 | -350.00 Mn |
| Sep 30, 2022 | -743.00 Mn |
| Jun 30, 2022 | 337.00 Mn |
| Mar 31, 2022 | -805.00 Mn |
| Dec 31, 2021 | -387.00 Mn |
| Sep 30, 2021 | -605.00 Mn |
| Jun 30, 2021 | 370.00 Mn |